Non-alcoholic steatohepatitis (NASH) is characterized by the presence of an abnormal accumulation of fat in the liver that can progress to cell injury and inflammation. Recent intervention studies have aimed to reduce the NASH-related metabolic stress and liver fat levels by decreasing the amount of lipid droplets in the hepatocyte, before inflammation and fibrosis become irreversible. Medical imaging is a powerful tool for measuring the effect of the intervention on liver fat. To incorporate effective imaging-based experiments into clinical trials for NASH, there are several factors to consider during the experimental design phase.
In this webinar, our featured speaker will discuss the following:
- Liver biology and metabolism basics, including the progression to non-alcoholic fatty liver disease (NAFLD) and NASH
- Use of non-invasive imaging to grade and monitor fatty liver diseases
- Measurements that are key for fat fraction analysis, inflammation and elastography
- Common imaging challenges and how to account for them
- Serum markers and their uses